Sandoz Group (OTCMKTS:SDZNY – Get Free Report) was upgraded by analysts at Jefferies Financial Group from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.
Sandoz Group Trading Up 0.0%
Shares of OTCMKTS:SDZNY opened at $85.73 on Thursday. The business has a 50-day moving average of $76.52 and a two-hundred day moving average of $67.49. Sandoz Group has a fifty-two week low of $35.61 and a fifty-two week high of $86.80. The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62.
Sandoz Group Company Profile
Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.
The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.
Read More
- Five stocks we like better than Sandoz Group
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Your Bank Account Is No Longer Safe
- The Next Commodity Crunch (bigger than oil?)
- What a Former CIA Agent Knows About the Coming Collapse
- Silicon Valley insiders hint at 12-month AI warning
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
